Previous 10 | Next 10 |
Sesen Bio ([[SESN]] -19.3%) has submitted marketing application to the FDA seeking approval for Vicineum, its lead candidate, for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer.Within 60 days after receipt of the completed application, the FDA w...
BLA supported by strong Phase 3 VISTA trial data and positive analytical comparability data Priority Review requested with potential approval in mid-2021 Estimated peak revenue of $1B-$3B globally, $400M-$900M projected in the US Sesen Bio (Nasdaq: SESN),...
The majority of the ICER Council (8 yes votes; 3 no votes) judged Vicineum as superior to best supportive care ICER report estimates that treatment with Vicineum results in a decrease in cumulative health care costs compared to usual care of approximate...
Investors Are Eyeing These 5 Penny Stocks This Week Throughout the pandemic, investors have worked to find penny stocks that may add value to their portfolios. While this can be easy for seasoned investors, newcomers may need a bit of advice to get started. With the introduction of ...
Looking For Biotech Penny Stocks Right Now? One of the most active sets of penny stocks in 2020 has been biotech stocks. Aside from the obvious push from COVID-19 vaccine candidates, companies are utilizing the increased attention to build upon novel treatment pipelines. Evidenced b...
Unique Pipelines Could Have These Penny Stocks On The Radar Before 2021 We talked about some biotech penny stocks earlier today and several took flight early. As the markets race to all-time highs once again, it’s no wonder why this sector is on fire. Countless companies are ...
Technology transfer to Qilu anticipated to be completed in mid-2021 Sesen Bio to receive $2M milestone payment upon completion of technology transfer Extensive biomanufacturing expertise and capacity positions Qilu Pharmaceutical to support anticipated significant glob...
4 Penny Stocks To Buy For Under $3; Are They Worth The Risk? As the pandemic rolls on, penny stocks remain a focus of day traders. Because the term “ penny stock ” simply refers to securities under $5, the options are almost limitless. But, as smart investors, we a...
Sesen Bio ([[SESN]] +3.6%) has received and analyzed all of the analytical comparability test results from the commercial-scale drug substance and drug product process performance qualification (“PPQ”) batches of Vicineum, its lead product candidate.For the manufacturing process...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical company and leading licensing partner in the Middle East and North Africa (...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...